Microbix Biosystms (MBX) AI Stock Analysis

• Market Cap: C$31.97M
• Dividend Yield: N/A
• Average Volume (3M): 57.61K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.39
• Revenue Growth: -26.81%
• EPS Growth: -161.24%
• Country: CA
• Employees: 100
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 138,986,940
• 10 Day Avg. Volume: 59,614
• 30 Day Avg. Volume: 57,610
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$0.50
• Price Target Upside: 117.39% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: C$0.21 ▼(-6.96% Downside)

Microbix Biosystems faces significant challenges in financial performance, with declining revenues and profitability issues. Technical analysis indicates bearish momentum, while valuation metrics are unattractive due to a negative P/E ratio. However, the earnings call provides some optimism with operational improvements and a strong financial position, aiming for recovery in fiscal 2026.

Positive Factors

Product Line Expansion

The introduction of the QUANTDx product line, which integrates earlier in assay development and sells at higher prices, positions Microbix to enhance its market presence and drive revenue growth, reflecting a strategic expansion of its product offerings.

Financial Stability

A strong balance sheet with a high current ratio and low debt-to-equity ratio provides Microbix with financial resilience, enabling it to withstand temporary setbacks and invest in growth opportunities.

Growth in Core Segments

The robust growth in the QAPs and antigen segments, despite setbacks from major clients, underscores the strength and potential of Microbix's core business areas, supporting long-term revenue expansion.

Negative Factors

Revenue Challenges

Significant revenue declines from key clients highlight customer concentration risks, which can impact financial performance and necessitate diversification to stabilize future earnings.

Margin Pressures

Persistent margin pressures from fixed costs and product mix challenges could constrain profitability, requiring strategic adjustments to improve cost efficiency and product offerings.

Market Uncertainty in China

The decline in demand for respiratory infection testing in China introduces uncertainty in a key market, potentially affecting future revenue streams and necessitating strategic market adjustments.

Microbix Biosystms Business Overview & Revenue Model

Company Description

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

How the Company Makes Money

Microbix Biosystems generates revenue primarily through the sale of its proprietary products, which include antigens and quality control materials used in diagnostic testing. Their revenue model is based on direct sales to diagnostic laboratories, pharmaceutical companies, and other healthcare providers. Key revenue streams include the sale of viral and bacterial antigens, which are vital for various tests, as well as quality control products that ensure the reliability of laboratory results. Additionally, the company benefits from partnerships with other biotech firms and research institutions, which can lead to collaborative projects and increased sales opportunities. Significant contracts and collaborations with major players in the diagnostics industry further enhance its revenue potential, allowing Microbix to expand its market presence and leverage its product offerings effectively.

Microbix Biosystms Financial Statement Overview

Summary

Microbix Biosystems is facing challenges in revenue growth and profitability, as reflected in the income statement. The balance sheet remains stable with manageable leverage, but recent profitability issues are concerning. Cash flow analysis indicates liquidity challenges despite improvements in free cash flow growth. Overall, the company needs to address revenue and profitability pressures to improve its financial health.

Income Statement

Microbix Biosystems has experienced a decline in revenue growth, with a negative growth rate of -12.06% in the latest year. The company also reported negative net income, resulting in a negative net profit margin. The gross profit margin remains relatively healthy at 53.01%, but the negative EBIT margin indicates operational challenges. Overall, the income statement reflects a company facing revenue and profitability pressures.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.24, indicating manageable leverage. However, the return on equity has turned negative, reflecting recent profitability issues. The equity ratio is stable, suggesting a solid capital structure. Overall, the balance sheet is stable but highlights concerns about recent profitability.

Cash Flow

Cash flow analysis reveals a significant increase in free cash flow growth, but the company still reports negative free cash flow. The operating cash flow to net income ratio is negative, indicating cash flow challenges. Despite improvements in free cash flow growth, the cash flow statement suggests liquidity concerns.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	18.59M	18.59M	25.39M	16.51M	19.08M	18.59M
Gross Profit	9.85M	9.85M	15.39M	7.48M	11.12M	11.04M
EBITDA	428.23K	428.23K	6.21M	1.96M	3.73M	5.66M
Net Income	-2.25M	-2.25M	3.52M	-39.48K	1.79M	1.63M
Balance Sheet
Total Assets	37.41M	37.41M	38.10M	35.65M	33.15M	28.83M
Cash, Cash Equivalents and Short-Term Investments	12.11M	12.11M	12.96M	11.61M	13.49M	9.99M
Total Debt	6.77M	6.77M	6.40M	6.65M	5.82M	7.74M
Total Liabilities	9.62M	9.62M	9.80M	11.03M	8.21M	10.27M
Stockholders Equity	27.79M	27.79M	28.30M	24.62M	24.94M	18.56M
Cash Flow
Free Cash Flow	-877.58K	-877.58K	2.44M	-2.11M	1.44M	804.20K
Operating Cash Flow	-80.29K	-80.29K	4.35M	-1.09M	3.47M	2.11M
Investing Cash Flow	-797.30K	-797.30K	-1.91M	-1.02M	-2.03M	-622.34K
Financing Cash Flow	27.00K	27.00K	-1.08M	229.21K	2.06M	8.41M

Microbix Biosystms Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.23
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MBX, the sentiment is Negative. The current price of 0.23 is below the 20-day moving average (MA) of 0.24, below the 50-day MA of 0.24, and below the 200-day MA of 0.29, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.47 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MBX.

Microbix Biosystms Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MBX	49 Neutral	C$31.97M	-14.56	-8.01%	―	-26.81%	-161.24%
BCT	43 Neutral	C$21.18M	-0.16	-409.25%	―	―	62.01%
DTC	30 Underperform	C$42.69M	-11.02	―	―	―	72.92%

Microbix Biosystms Corporate Events

Microbix Biosystems to Engage with Investors at Muskoka Capital Event

Microbix Biosystems Inc. announced its participation in the Muskoka Capital Event, where its CEO and COO will engage in one-on-one meetings with growth-oriented investors. This event is an opportunity for Microbix to enhance its visibility among investors and potentially secure financing and market support. The company’s participation underscores its proactive approach in engaging with the investment community to bolster its market presence and operational growth.

The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix and EMQN Launch EQA Program for Genetic Testing in Clopidogrel Dosing

Microbix Biosystems Inc. and EMQN CIC have launched a new external quality assessment (EQA) program to improve the accuracy of genetic testing for patients prescribed the anti-clotting drug Clopidogrel. This initiative aims to ensure that patients with gene variants affecting drug metabolism receive appropriate dosing, thereby reducing the risk of life-threatening bleeding or clots. The program utilizes Microbix’s quality assessment products to help laboratories maintain testing proficiency, ultimately aiding physicians and pharmacists in making informed prescription decisions. This collaboration marks Microbix’s second venture into supporting genetic test accuracy, complementing its established roles in infectious diseases and oncology.

The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix and Labquality Launch EQA Program for Accurate HPV-Related Cancer Diagnosis

Microbix Biosystems Inc. and Labquality Oy have launched a novel external quality assessment (EQA) program to help clinical laboratories accurately identify head and neck cancers associated with HPV. This initiative addresses a critical need in the diagnostics industry by providing proficiency testing for labs, using Microbix’s QAPs that emulate clinical specimens. The program aims to enhance diagnostic accuracy, reduce subjectivity in test interpretation, and prevent inappropriate treatment decisions, thereby supporting labs in achieving high-quality assurance standards.

The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix Hosts Ontario Minister to Showcase Biotech Innovations

Microbix Biosystems Inc. recently hosted Ontario’s Minister of Public and Business Service Delivery, Stephen Crawford, at its biotechnology manufacturing facilities in Mississauga. The visit highlighted the company’s role in advancing next-generation diagnostics to improve health outcomes and reduce healthcare costs. Supported by Ontario’s government with significant grant funding, Microbix has developed state-of-the-art manufacturing capabilities and world-leading healthcare products. The company’s operations contribute to economic growth and job creation in Ontario, emphasizing its commitment to innovation and quality in the life sciences sector.

The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix Biosystems Navigates Challenges with Strategic Growth

Microbix Biosystems’ latest earnings call painted a picture of a challenging quarter, marked by significant revenue setbacks with two major clients. This led to the weakest performance in three years. Despite these hurdles, the company remains financially stable, with promising new product developments and ongoing progress in the Kinlytic project. The company is poised for future growth, building on strong financials and expanding product lines.

Microbix Biosystems Faces Revenue Decline Amid Market Challenges

Microbix Biosystems reported a challenging third quarter for fiscal 2025, with revenues falling to $3.5 million, a 31% decrease from the previous year, primarily due to reduced sales in China and the cancellation of test-development programs by a key customer. Despite a strong cash position, the company experienced a net loss of $1.64 million, driven by weaker gross margins and increased operating expenses. The year-to-date performance also saw a decline in revenues and margins, leading to an operating loss, although antigen sales showed some growth. The company’s financial ratios improved, indicating a strong liquidity position, but the outlook remains cautious due to ongoing challenges in key markets.

The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix Biosystems to Announce Q3 Fiscal 2025 Results

Microbix Biosystems Inc. announced the upcoming release of its Q3 fiscal 2025 financial results, scheduled for August 14, 2025, followed by a webinar discussion with the company’s executives. This announcement is significant for stakeholders as it provides insights into the company’s financial health and operational performance, potentially impacting its market positioning and investor confidence.

The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.